

Synthesis and Iodocyclization of Homoallylic Hydroxylamines

Andrea Fiumana, Marco Lombardo, and Claudio Trombini*

Dipartimento di Chimica "G. Ciamician",
Università di Bologna, via Selmi 2, I-40126 Bologna, Italy

Received March 24, 1997

The allylation of nitrogen derivatives of carbonyl compounds such as imines and oximes,¹ etc., has received special attention due to the synthetic versatility of the final homoallylic amines and their applications as chiral modifiers or auxiliaries in asymmetric synthesis.

We recently reported the simple allylation of prochiral and chiral nitrones with allylmagnesium chloride; the resulting homoallylic *N*-hydroxylamines were exploited in iodocyclization reactions to give 5-(iodomethyl)isoxazolidines.²

We now wish to report that allylic zinc bromides generated *in situ* from allylic bromides **1** and zinc powder in THF regioselectively add to model aldonitrones **2** in very good yields. The simple diastereoselectivity of reactions involving crotylzinc bromide and the facial selectivity displayed by allylzinc bromide toward the *N*-benzyl nitronone of glyceraldehyde were examined. Finally, homoallylic hydroxylamines **3** were *O*-silylated and subjected to iodocyclization to **4** in order (i) to get information about the *syn/anti* stereorelationship in hydroxylamines **3** and (ii) to observe stereodirecting effects of methyl substituents on the isoxazolidine-forming reaction (Scheme 1). In a first set of experiments (Table 1), we examined the allylation, crotylation, and prenylation of *O*-benzyl glycolaldehyde *N*-benzyl nitronone. Reaction rates were found to be dependent on the degree of substitution on the allylic moiety, as expected on steric grounds (Table 1, entries 1, 2, and 6), the prenyl complex being the least reactive. The crotyl complex displayed an *anti* diastereoselectivity. Interesting observations were made when the reaction was carried out in the presence of Et₂AlCl (DEAC). Independent of the order of addition, reaction rates tremendously increased, the addition step could be carried out at much lower temperature, and a reversed *syn* selectivity was displayed (Table 1, entries 4 and 5). We also tested the crotylation of benzaldehyde *N*-methyl nitronone, and again, we observed the inversion of simple diastereopreference with and without DEAC. The results are reported in Table 2. The *syn* selectivity displayed by DEAC could be accounted for by the adoption of an acyclic anti-




Table 1. Reaction of *O*-Benzyl Glycolaldehyde *N*-Benzyl nitronone with Allylic Zinc Complexes

entry	1 (method) ^a	<i>T</i> (°C)	<i>t</i> (h)	product ^b (%)	<i>syn/anti</i> ^c
1	allyl (A)	25	0.5	3a (94)	
2	crotyl (A)	25	3.5	3b (95)	1/4
3	crotyl (A)	-40	4	3b (23)	1/5
4	crotyl (B)	-40	1.5	3b (91)	4/1
5	crotyl (C)	-40	1.5	3b (89)	4/1
6	prenyl (A)	25	24	3c (59)	
7	prenyl (B)	-40	1	3c (38)	
8	prenyl (B)	20	1	3c (80)	

^a Method A involves the addition of the allylic zinc complex to nitronone at the reported temperature. Method B involves the addition of the allylic zinc complex to a pre-equilibrated mixture of nitronone and DEAC. Method C involves the addition of nitronone at -40 °C to a pre-equilibrated mixture of crotylzinc bromide and DEAC. ^b Isolated yield. ^c Determined by integral ratios in the ¹H NMR of crude reaction mixture.

Table 2. Reaction of Benzaldehyde *N*-Methyl nitronone with Crotylzinc Bromide

entry	method ^a	<i>T</i> (°C)	<i>t</i> (h)	3d ^b (%)	<i>syn/anti</i> ^c
1	A	25	24	80	3/7
2	A	-40	24	traces	not det
3	B	-40	1	38	9/1

^{a-c} See corresponding footnotes in Table 1.

periplanar transition state (TS); this TS geometry explains the stereoconvergent *syn* selectivity in the addition of crotylstannanes to aldehydes in the presence of Lewis acids, independent of the crotyl double bond configuration.³ In the absence of DEAC, synclinal TS's, leading to the *anti* product, could be stabilized by attractive interactions between nitronone oxygen and zinc atom.^{3b}

The last set of experiments was performed on (*R*)-glyceraldehyde acetonide *N*-benzyl nitronone (Table 3). Using allylzinc bromide, we observed a slightly higher diastereofacial *anti* selectivity with respect to the previously reported allylmagnesium chloride^{2b} (Table 3, entries 1 and 2). Again, an inversion of diastereopreference was

(3) (a) Yamamoto, Y.; Yatagai, H.; Ishihara, Y.; Maeda, N.; Maruyama, K. *Tetrahedron* **1984**, *40*, 2239. (b) Nishigaichi, Y.; Takuwa, A.; Naruta, Y.; Maruyama, K. *Tetrahedron* **1993**, *49*, 7395.

* To whom correspondence should be addressed: Tel.: 51-259513. Fax: 51-259456. E-mail: trombini@ciam.unibo.it.

(1) Owing to the huge number of references on this topic, we only refer to the most recent papers and to references therein: (a) Itsuno, S.; Watanabe, K.; Ito, K.; El-Shehaw, A. A.; Sarhan, A. A. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 109. (b) Nakamura, H.; Iwama, H.; Yamamoto, Y. *J. Am. Chem. Soc.* **1996**, *118*, 6641. (c) Nakamura, M.; Hirai, A.; Nakamura, E. *J. Am. Chem. Soc.* **1996**, *118*, 8489. (d) Alvaro, G.; Savoia, D. *Tetrahedron: Asymmetry* **1996**, *7*, 2083. (e) Alvaro, G.; Boga, C.; Savoia, D.; Umani-Ronchi, A. *J. Chem. Soc. Perkin Trans. 1* **1996**, 875. (f) Hanessian, S.; Yang, R.-Y. *Tetrahedron Lett.* **1996**, *37*, 5273. (g) Wang, D.-K.; Dai, L.-X.; Hou, X.-L.; Zhang, Y. *Tetrahedron Lett.* **1996**, *37*, 4187. (h) Wang, J.; Zhang, Y.; Bao, W. *Synth. Commun.* **1996**, *26*, 2473. (i) Yanagisawa, A.; Ogasawara, K.; Yasue, K.; Yamamoto, H. *J. Chem. Soc., Chem. Commun.* **1996**, 367.

(2) (a) Mancini, F.; Piazza, M. G.; Trombini, C. *J. Org. Chem.* **1991**, *56*, 4246. (b) Dhavale, D. D.; Gentilucci, L.; Piazza, M. G.; Trombini, C. *Liebigs Ann. Chem.* **1992**, 1289.

Table 3. Reaction of (*R*)-Glyceraldehyde Acetonide *N*-Benzylnitronone with Allylzinc Bromide

entry	method ^a	<i>T</i> (°C)	<i>t</i> (h)	3e ^b (%)	<i>syn/anti</i> ^c
1 ^a	<i>d</i>	-30	2	90	44/56
2	A	0	1	92	25/75
3	B	0	0.5	88	58/42
4	B	-40	0.5	80	65/35

^{a-c} See corresponding notes to Table 1. ^d Reaction carried out with allylmagnesium chloride, taken from ref 2b.


Table 4. Iodocyclization Reaction of *O*-Silylated Hydroxylamines **3 Promoted by NIS**

entry	substrate	<i>t</i> (h)	products ^a (%)
1	3a	2	3,5- <i>cis</i> - 4a (41) + 3,5- <i>trans</i> - 4a (50)
2	<i>syn</i> - 3b ^b	3	4b (traces)
3	<i>anti</i> - 3b ^c	3	3,4- <i>trans</i> -4,5- <i>trans</i> - 4b (56) + 3,4- <i>trans</i> -4,5- <i>cis</i> - 4b (19)
4	3c	4	3,5- <i>trans</i> - 4c (41) ^d
5	<i>syn</i> - 3d ^e	3	3,4- <i>cis</i> -4,5- <i>trans</i> - 4d (55)
6	<i>anti</i> - 3d ^f	3	3,4- <i>trans</i> -4,5- <i>trans</i> - 4d (58)

^a Isolated yields. ^b Reaction carried out on an 80% enriched mixture of the reported isomer. ^c Reaction carried out on an 80% enriched mixture of the reported isomer. ^d No trace of 3,5-*cis* isomer was observed and isolated. ^e Reaction carried out on a 90% enriched mixture of the reported isomer. ^f Reaction carried out on a 70% enriched mixture of the reported isomer.

recorded in the presence of DEAC, even though the absolute level of stereoselectivity was not impressive. An analogous reversal of facial stereoselection had previously been reported by Dondoni in the addition of nucleophiles such as 2-lithiothiazole,⁴ 2-lithiofuran,⁵ and simple Grignard reagents⁶ to chiral nitrones in the presence of DEAC.

A classical solution to the assignment of the relative stereochemistry of contiguous centers requires their incorporation on the ring system of a 5- or 6-membered cyclic derivative. The iodocyclization reaction of products **3** to isoxazolidines **4** not only allowed us to establish the *syn/anti* stereorelationships of **3b** and **3d** by inspecting coupling constants and NOE effects⁷ on H-3 and H-4 of **4** but also gave interesting information about the effect of methyl groups on the ring closure process. The reactions were promoted by *N*-iodosuccinimide (NIS) in chloroform at 0 °C. The results are summarized in Table 4. Hydroxylamine **3a** afforded the expected mixture of 3,5-*cis* and 3,5-*trans* products on the basis of previous results on related hydroxylamines (Table 4, entry 1).^{2a} Interestingly, the presence of two methyl groups on **3c** completely inhibited the formation of the 3,5-*cis* product (Table 4, entry 4). As far as homoallylic hydroxylamines **3b** and **3d** are concerned, the methyl group confers a marked preference for the formation of the 4,5-*trans* isoxazolidines, which are the sole products in entries 5 and 6 (Table 4) and the major one in entry 3 (Table 4). In general, products possessing the 3,4-*cis*-4,5-*cis* stereochemistry were never detected; in particular, hydroxylamine *syn*-**3b** underwent only oxidative decomposition into a plethora of unidentified products upon standing with NIS.⁸ On the other hand, *N*-methylhydroxylamine *syn*-**3d** proved to be less sensitive to oxidative

Scheme 2

decomposition than *N*-benzylhydroxylamine *syn*-**3b** and was stereoselectively converted into 3,4-*cis*-4,5-*trans*-isoxazolidine **4d**. Noteworthy is that entry 6 represents the only iodocyclization experiment so far reported by us in which a product coming from a 4-*exo-trig* ring closure (Scheme 2, path B) has been observed. In fact, we isolated, besides isoxazolidine 3,4-*trans*-4,5-*trans*-**4d** coming from the normal 5-*exo-trig* mode (path A), azetidine *N*-oxide **5d** in 17% yield.

In conclusion, regiocontrolled allylation of nitrones combined with the iodocyclization reaction of the resulting homoallylic hydroxylamines could offer an interesting route to highly functionalized carbon frameworks. The attainment of the best stereocontrol in this process is the goal of our present studies.

Experimental Section

General Methods. All reactions were carried out in oven-dried glassware under an atmosphere of dry argon. All reagents were commercially available and were used without further purification, unless otherwise stated. ¹H and ¹³C NMR were recorded at 300 and 75 MHz, respectively, using tetramethylsilane as an internal standard. Melting points are uncorrected.

Glycolaldehyde *N*-Benzylnitronone. 2-(Benzyloxy)ethanal (1.0 g, 6.7 mmol) and *N*-benzylhydroxylamine, freshly freed from the hydrochloride (1.07 g, 6.7 mmol), were allowed to react in CH₂Cl₂ (5 mL) at 20 °C overnight. After solvent evaporation and recrystallization (cyclohexane:ether) the pure nitronone (1.71 g, 97%) was obtained as a white solid: mp 95–96 °C; ¹H NMR (CDCl₃) δ 4.48 (d, *J* = 4.1 Hz, 2H), 4.54 (s, 2H), 4.87 (s, 2H), 6.79 (t, *J* = 4.1 Hz, 1H), 7.32–7.40 (m, 10H); ¹³C NMR (CDCl₃) δ 66.1, 69.0, 73.8, 127.9, 128.0, 128.5, 129.0, 129.2, 129.6, 132.0, 137.1, 137.4. Anal. Calcd for C₁₆H₁₅NO₂: C, 75.26; H, 6.72; N, 5.49. Found: C, 75.31; H, 6.58; N, 5.33.

Preparation of Allylic Zinc Bromide Solutions. To a suspension of activated zinc powder⁹ (1.1 g, 16.8 mmol) in anhydrous THF (5 mL) was added a solution of allyl bromide (0.36 mL, 4.2 mmol) in THF (2 mL) at 0 °C. The heterogeneous mixture was allowed to reach rt and stirred for 2 h. After filtration through a glass frit under argon, the resulting solution of organozinc complex was titrated¹⁰ and directly used for the addition reaction. For the preparation of crotyl- and prenylzinc bromide solutions, the corresponding allylic bromide was stirred with zinc at 0 °C for 3 h, so avoiding a Wurtz-type side reaction.

***N*-Hydroxy-*N*-benzyl-1-(benzyloxy)-4-penten-2-amine (**3a**). Method A (Table 1, Entry 1).** A solution of allylzinc bromide (5 mL, 0.6 M, 3 mmol) was added to glycolaldehyde *N*-benzylnitronone (383 mg, 1.5 mmol) dissolved in THF (2 mL), and the solution was stirred at rt for 30 min. The reaction mixture was quenched with aqueous NaHCO₃, filtered (Celite), and extracted

(8) In three different experiments we got untractable reaction mixtures; after thiosulfate quenching, we identified a significant amount of benzaldehyde. We believe that oxidation might convert the starting *N*-benzyl group into a *C*-phenyl nitronone, which undergoes hydrolysis to benzaldehyde on aqueous workup.

(9) A number of methods for the activation of zinc or for the *in situ* preparation of active forms of zinc are available; see, for example (a) Rieke, R. D.; Hanson, M. V. *Tetrahedron* **1997**, *53*, 1925. (b) Erdik, E. *Tetrahedron* **1987**, *43*, 2203. For our purposes, activation was simply carried out by heating zinc powder (Janssen) at about 300 °C with a heat gun for 5 min under argon.

(10) An aliquot of allylic zinc bromide solution was quenched with 1 N HCl, and zinc was titrated by EDTA.

(4) Dondoni, A.; Franco, S.; Junquera, F.; Merchan, F. L.; Merino, P.; Tejero, T.; Bertolasi, V. *Chem. Eur. J.* **1995**, *1*, 505.

(5) Dondoni, A.; Junquera, F.; Merchan, F. L.; Merino, P.; Tejero, T. *Synthesis* **1994**, 1450.

(6) Merchan, F.; Merino, P.; Rojo, P.; Tejero, T.; Dondoni, A. *Tetrahedron: Asymmetry* **1996**, *7*, 667.

(7) The following ranges of NOE values were observed: *cis* H-3/H-4 and *cis* H-4/H-5 5–8%; *trans* H-3/H-4 and *trans* H-4/H-5 <2%; *cis* H-4/CH₂I and *cis* H-4/CH₂OBN 3–5%.

with ether (3 × 5 mL). The combined organic layers were dried (Na₂SO₄) and concentrated at reduced pressure. Hydroxylamine **3a** was obtained as a yellow oil (420 mg, 94%) after purification using flash chromatography (cyclohexane:ethyl acetate 95/5). **3a**: ¹H NMR (CDCl₃) δ 2.36 (dt, *J* = 7.6/14.3 Hz, 1H), 2.52 (dt, *J* = 6.0/14.3 Hz, 1H), 3.07 (ddt, *J* = 4.2/6.0/7.6 Hz, 1H), 3.63 (dd, *J* = 4.2/10.1 Hz, 1H), 3.78 (dd, *J* = 6.0/10.1 Hz, 1H), 3.97 (s, 2H), 4.54 (s, 2H), 5.03–5.12 (m, 2H), 5.19 (br s, 1H), 5.86 (ddt, *J* = 6.0/7.6/13.8 Hz, 1H), 7.28–7.40 (m, 10H); ¹³C NMR (CDCl₃) δ 32.8, 60.7, 64.9, 69.4, 73.2, 116.5, 127.1, 127.6, 128.2, 128.4, 129.2, 136.0, 138.2, 138.4. Anal. Calcd for C₁₉H₂₃N₂O₂: C, 76.72; H, 7.80; N, 4.71. Found: C, 76.92; H, 7.75; N, 4.83.

Method B (Table 1, Entry 4). Nitron (383 mg, 1.5 mmol) and DEAC (~1.8 M in hexane, 0.82 mL) in THF (2 mL) were equilibrated at -40 °C for 20 min. At the same temperature, a solution of crotylzinc bromide (6 mL, 0.5 M, 3 mmol) was added, and the reaction mixture was stirred for 1.5 h.

Method C (Table 1, Entry 5). A solution of crotylzinc bromide (5 mL, 0.16 M, 0.8 mmol) was treated with DEAC (0.21 mL, 0.8 mmol) at -40 °C for 30 min. Solid nitron (100 mg, 0.39 mmol) was added at -40 °C, and stirring was continued for 1.5 h.

***N*-Hydroxy-*N*-benzyl-1-(benzyloxy)-3-methyl-4-penten-2-amine (3b).** The product was obtained as a solid mixture of the two *syn/anti* isomers having the same *R*_f on silica gel. The following spectroscopic data were drawn from the enriched mixtures obtained in entries 3 and 4 of Table 1. *syn-3b*: ¹H NMR (CDCl₃) δ 1.17 (d, *J* = 6.8 Hz, 3H), 2.54–2.67 (m, 1H), 2.82 (ddd, *J* = 3.0/5.8/8.7 Hz, 1H), 3.75 (dd, *J* = 3.0/10.2 Hz, 1H), 3.87 (dd, *J* = 5.8/10.2 Hz, 1H), 3.92 (d, *J* = 13.7 Hz, 1H), 4.16 (d, *J* = 13.7 Hz, 1H), 4.53 (s, 2H), 4.99 (ddd, *J* = 0.7/1.9/10.2 Hz, 1H), 5.05 (ddd, *J* = 1.0/1.9/17.2 Hz, 1H), 5.32 (br s, 1H), 5.79 (ddd, *J* = 8.3/10.2/17.2 Hz, 1H), 7.20–7.42 (m, 10H); ¹³C NMR (CDCl₃) δ 18.1, 38.8, 61.3, 68.9, 73.4, 80.9, 114.5, 127.1, 127.7, 128.3, 128.4, 128.7, 130.3, 135.7, 139.1, 141.8. *anti-3b*: ¹H NMR (CDCl₃) δ 1.08 (d, *J* = 6.8 Hz, 3H), 2.52–2.67 (m, 1H), 2.89 (ddd, *J* = 3.2/5.7/7.4 Hz, 1H), 3.73 (dd, *J* = 3.2/10.2 Hz, 1H), 3.78 (dd, *J* = 5.7/10.2 Hz, 1H), 3.88 (d, *J* = 13.9 Hz, 1H), 4.15 (d, *J* = 13.9 Hz, 1H), 4.56 (s, 2H), 5.00–5.07 (m, 2H), 5.39 (br s, 1H), 5.97 (ddd, *J* = 7.7/10.3/17.1 Hz, 1H), 7.21–7.38 (m, 10H); ¹³C NMR (CDCl₃) δ 17.4, 38.4, 60.6, 67.1, 69.6, 73.2, 113.3, 127.0, 127.6, 128.1, 128.2, 128.4, 129.4, 138.3, 138.9, 142.8. Anal. (of a purified mixture of *syn-3b/anti-3b* in a 4:1 ratio) Calcd for C₂₀H₂₅N₂O₂: C, 77.12; H, 8.10; N, 4.50. Found: C, 77.36; H, 8.04; N, 4.21.

***N*-Hydroxy-*N*-benzyl-1-(benzyloxy)-3,3-dimethyl-4-penten-2-amine (3c):** Oil; ¹H NMR (CDCl₃) δ 1.10 (s, 3H), 1.14 (s, 3H), 2.83 (dd, *J* = 3.5/6.9 Hz, 1H), 3.69 (dd, *J* = 3.5/10.3 Hz, 1H), 3.95 (d, *J* = 13.7 Hz, 1H), 4.15 (dd, *J* = 6.9/10.3 Hz, 1H), 4.24 (d, *J* = 13.7 Hz, 1H), 4.51 (br s, 1H), 4.54 (d, *J* = 11.8 Hz, 1H), 4.60 (d, *J* = 11.8 Hz, 1H), 4.96 (dd, *J* = 1.4/10.7 Hz, 1H), 4.99 (dd, *J* = 1.4/17.5 Hz, 1H), 5.98 (dd, *J* = 10.7/17.5 Hz, 1H), 7.25–7.42 (m, 10H); ¹³C NMR (CDCl₃) δ 24.4, 26.1, 40.7, 64.0, 66.6, 72.8, 73.2, 111.1, 126.9, 127.5, 127.6, 128.2, 128.4, 129.1, 138.4, 139.2, 146.8. Anal. Calcd for C₂₁H₂₇N₂O₂: C, 77.49; H, 8.37; N, 4.31. Found: C, 77.71; H, 8.56; N, 4.62.

***N*-Methyl-α-(1-methyl)-2-propenylbenzenemethanamine (3d).** The product was obtained as a mixture of the two *syn/anti* isomers having the same *R*_f on silica gel. The following spectroscopic data were drawn from the enriched mixtures obtained in entries 1 and 3 of Table 2. *syn-3d*: ¹H NMR (CDCl₃) δ 0.95 (d, *J* = 6.9 Hz, 3H), 2.53 (s, 3H), 3.00–3.08 (m, 1H), 3.41 (d, *J* = 2.2 Hz, 1H), 4.95–5.00 (m, 2H), 5.75–5.87 (m, 1H), 7.26–7.35 (m, 5H); ¹³C NMR (CDCl₃) δ 17.6, 39.2, 46.3, 78.8, 114.6, 127.4, 127.8, 128.5, 129.6, 137.5, 140.4. *anti-3d*: ¹H NMR (CDCl₃) δ 0.85 (d, *J* = 6.8 Hz, 3H), 2.44 (s, 3H), 2.90–2.99 (m, 1H), 3.38 (s, 1H), 4.73 (br s, 1H), 5.05 (ddd, *J* = 0.6/1.9/10.2 Hz, 1H), 5.13 (ddd, *J* = 0.9/1.9/17.1 Hz, 1H), 5.87 (ddd, *J* = 8.6/10.2/17.1 Hz, 1H), 7.25–7.40 (m, 5H); ¹³C NMR (CDCl₃) δ 16.9, 40.7, 45.4, 77.9, 113.5, 127.4, 127.8, 128.4, 128.7, 137.0, 143.2. Anal. (of a purified mixture of *syn-3d/anti-3d* in a 7:3 ratio) Calcd for C₁₂H₁₇NO: C, 75.34; H, 8.96; N, 7.33. Found: C, 75.38; H, 8.84; N, 7.52.

2-Benzyl-3-[(benzyloxy)methyl]-5-(iodomethyl)isoxazolidine (4a). General Procedure for the Iodocyclization Reaction. Imidazole (190 mg, 2.8 mmol) and TMSCl (0.36 mL, 2.8 mmol) were added to a solution of **3a** (420 mg, 1.4 mmol) in

dry CH₂Cl₂ (5 mL), and the reaction mixture was stirred at rt overnight. Hexane (2 mL) was added, and the solution was filtered (Celite) and evaporated under reduced pressure to afford silylated hydroxylamine (442 mg, 86%) as a dense oil.¹¹ The product was dissolved in CHCl₃ (5 mL), the solution was cooled at 0 °C, and NIS (540 mg, 2.4 mmol) was added. After being stirred in the dark for 2 h at 0 °C, the reaction was quenched with aqueous Na₂S₂O₃, and the aqueous layer was extracted with CHCl₃ (3 × 5 mL). *cis-4a* (208 mg, 41%) and *trans-4a* (254 mg, 50%) were separated using flash chromatography eluting with cyclohexane/ethyl acetate 95:5. *3,5-cis-4a*: oil; ¹H NMR (CDCl₃) δ 1.92 (dt, *J* = 6.2/12.7 Hz, 1H), 2.66 (dt, *J* = 7.9/12.7 Hz, 1H), 3.13 (dd, *J* = 8.4/9.6 Hz, 1H), 3.29 (dd, *J* = 5.0/9.6 Hz, 1H), 3.29–3.38 (m, 1H), 3.49 (dd, *J* = 5.8/9.6 Hz, 1H), 3.57 (dd, *J* = 6.9/9.6 Hz, 1H), 3.99 (d, *J* = 13.8 Hz, 1H), 4.12 (d, *J* = 13.8 Hz, 1H), 4.39 (m, 1H), 4.49 (d, *J* = 12.0 Hz, 1H), 4.55 (d, *J* = 12.0 Hz, 1H), 7.22–7.40 (m, 10H); ¹³C NMR (CDCl₃) δ 8.1, 38.3, 61.5, 65.0, 71.8, 73.3, 76.6, 127.2, 127.7, 128.2, 128.4, 128.8, 136.2, 139.8. Anal. Calcd for C₁₉H₂₂N₂O₂I: C, 53.89; H, 5.24; N, 3.31. Found: C, 53.96; H, 4.98; N, 3.28. *3,5-trans-4a*: oil; ¹H NMR (CDCl₃) δ 2.18 (dt, *J* = 7.8/12.7 Hz, 1H), 2.30 (dt, *J* = 7.3/12.7 Hz, 1H), 3.15 (dd, *J* = 8.0/9.9 Hz, 1H), 3.30 (dd, *J* = 4.7/9.9 Hz, 1H), 3.27–3.34 (m, 1H), 3.53 (d, *J* = 5.5 Hz, 2H), 4.01 (d, *J* = 13.7 Hz, 1H), 4.12 (br dq, *J* = 4.7/7.7 Hz, 1H), 4.24 (d, *J* = 13.7 Hz, 1H), 4.52 (s, 2H), 7.26–7.41 (m, 10H); ¹³C NMR (CDCl₃) δ 8.3, 38.6, 62.7, 64.4, 71.3, 73.4, 76.6, 127.2, 127.6, 127.7, 128.2, 128.4, 129.1, 135.5, 137.9. Anal. Calcd for C₁₉H₂₂N₂O₂I: C, 53.89; H, 5.24; N, 3.31. Found: C, 53.72; H, 5.12; N, 3.47.

2-Benzyl-3-[(benzyloxy)methyl]-5-(iodomethyl)-4-methylisoxazolidine (4b). *3,4-trans-4,5-trans-4b*: oil; ¹H NMR (CDCl₃) δ 1.24 (d, *J* = 6.8 Hz, 3H), 2.09–2.26 (m, 1H), 2.85 (dt, *J* = 5.6/11.7 Hz, 1H), 3.28 (d, *J* = 6.4 Hz, 2H), 3.59 (d, *J* = 5.6 Hz, 2H), 3.82 (q, *J* = 6.4 Hz, 1H), 3.94 (d, *J* = 14.0 Hz, 1H), 4.31 (d, *J* = 14.0 Hz, 1H), 4.53 (s, 2H), 7.22–7.40 (m, 10H); ¹³C NMR (CDCl₃) δ 8.0, 18.2, 47.2, 61.7, 71.1, 73.2, 73.3, 82.6, 127.0, 127.5, 127.6, 128.1, 128.4, 128.7, 137.8, 137.9. Anal. Calcd for C₂₀H₂₄N₂O₂I: C, 54.91; H, 5.53; N, 3.20. Found: C, 54.65; H, 5.61; N, 3.37. *3,4-trans-4,5-cis-4b*: oil; ¹H NMR (CDCl₃) δ 1.09 (d, *J* = 7.1 Hz, 3H), 2.40–2.51 (m, 1H), 2.79–2.85 (m, 1H), 3.07 (dd, *J* = 7.8/10.0 Hz, 1H), 3.18 (dd, *J* = 6.2/10.0 Hz, 1H), 3.52–3.57 (m, 2H), 3.98 (d, *J* = 14.0 Hz, 1H), 4.24–4.34 (m, 1H), 4.26 (d, *J* = 14.0 Hz, 1H), 4.51 (d, *J* = 12.0 Hz, 1H), 4.55 (d, *J* = 12.0 Hz, 1H), 7.27–7.40 (m, 10H); ¹³C NMR (CDCl₃) δ 1.3, 13.5, 42.3, 62.9, 71.6, 72.6, 73.4, 79.2, 127.2, 127.6, 127.7, 128.2, 128.4, 129.3, 137.4, 137.9. Anal. Calcd for C₂₀H₂₄N₂O₂I: C, 54.91; H, 5.53; N, 3.20. Found: C, 55.12; H, 5.58; N, 3.14.

2-Benzyl-3-[(benzyloxy)methyl]-5-(iodomethyl)-4,4-dimethylisoxazolidine (4c). *3,5-trans-4c*: oil; ¹H NMR (CDCl₃) δ 1.13 (s, 6H), 3.06 (d, *J* = 6.6 Hz, 1H), 3.34 (dd, *J* = 6.6/11.2 Hz, 1H), 3.65 (d, *J* = 15.3 Hz, 1H), 3.75 (d, *J* = 11.2 Hz, 1H), 3.88 (dd, *J* = 4.4/11.0 Hz, 1H), 4.13 (t, *J* = 11.0 Hz, 1H), 4.22 (dd, *J* = 4.4/11.0 Hz, 1H), 4.26 (d, *J* = 15.3 Hz, 1H), 4.46 (d, *J* = 11.8 Hz, 1H), 4.51 (d, *J* = 11.8 Hz, 1H), 7.21–7.38 (m, 10H); ¹³C NMR (CDCl₃) δ 27.7, 37.5, 45.8, 59.3, 69.5, 72.6, 72.9, 73.8, 126.6, 127.6, 127.8, 127.9, 128.1, 128.5, 137.5, 139.2. Anal. Calcd for C₂₁H₂₆N₂O₂I: C, 55.86; H, 5.81; N, 3.10. Found: C, 55.73; H, 5.92; N, 3.14.

5-(Iodomethyl)-2,4-dimethyl-3-phenylisoxazolidine (4d). *3,4-cis-4,5-trans-4d*: oil; ¹H NMR (CDCl₃) δ 0.76 (d, *J* = 7.3 Hz, 3H), 2.53 (ddq, *J* = 5.7/7.3/8.3 Hz, 1H), 2.68 (s, 3H), 3.33 (dd, *J* = 5.7/10.4 Hz, 1H), 3.38 (dd, *J* = 5.7/10.4 Hz, 1H), 3.72 (q, *J* = 5.7 Hz, 1H), 3.77 (d, *J* = 8.3 Hz, 1H), 7.20–7.40 (m, 5H); ¹³C NMR (CDCl₃) δ 7.2, 15.8, 44.0, 48.1, 76.2, 83.7, 127.5, 128.2, 128.3, 136.8. Anal. Calcd for C₁₂H₁₆NOI: C, 45.42; H, 5.09; N, 4.42. Found: C, 45.38; H, 5.24; N, 4.46. *3,4-trans-4,5-trans-4d*: oil; ¹H NMR (CDCl₃) δ 1.18 (d, *J* = 6.8 Hz, 3H), 2.38 (ddq, *J* = 5.7/6.8/9.3 Hz, 1H), 2.55 (s, 3H), 3.10 (d, *J* = 9.3 Hz, 1H), 3.41 (dd, *J* = 7.7/9.7 Hz, 1H), 3.48 (dd, *J* = 5.7/9.7 Hz, 1H), 3.96 (dt, *J* = 5.7/7.7 Hz, 1H), 7.28–7.40 (m, 5H); ¹³C NMR (CDCl₃) δ 9.3, 16.9, 43.3, 54.1, 82.4, 83.1, 127.8, 128.1, 128.7, 137.5. Anal.

(11) All the *O*-silylated hydroxylamines, contrary to starting hydroxylamines, are easily analyzed by GC-MS and show the characteristic fragment due to the loss of the allylic moiety from the molecular ion.

Calcd for C₁₂H₁₆NOI: C, 45.42; H, 5.09; N, 4.42. Found: C, 45.48; H, 5.02; N, 4.51.

2-(Iodomethyl)-1,3-dimethyl-4-phenylazetidine 1-Oxide (5d). Oil; ¹H NMR (CDCl₃) δ 1.22 (d, *J* = 6.8 Hz, 3H), 2.31 (ddq, *J* = 5.8/6.8/8.8 Hz, 1H), 2.70 (q, *J* = 5.8 Hz, 1H), 2.91 (s, 3H), 3.31 (dd, *J* = 5.8/10.4 Hz, 1H), 3.37 (dd, *J* = 5.8/10.4 Hz, 1H), 4.81 (d, *J* = 8.8 Hz, 1H), 7.30–7.42 (m, 5H); ¹³C NMR (CDCl₃) δ 8.0, 16.4, 46.2, 54.3, 76.4, 106.8, 127.2, 128.7, 129.0, 135.4.

Anal. Calcd for C₁₂H₁₆NOI: C, 45.42; H, 5.09; N, 4.42. Found: C, 45.36; H, 5.17; N, 4.48.

Acknowledgment. We thank the University of Bologna (funds for selected topics) and Italian CNR for financial support.

JO970544S